Lilly Invests $7.5M in Indiana Biosciences

Eli Lilly and Co. is investing $7.5 million toward startup of the Indiana Biosciences Research Institute. “This represents a significant investment by Lilly in the future of Indiana and in the future of biosciences research,” said John C. Lechleiter, Ph.D., chairman and chief executive officer of Lilly. “Each year in Indiana, billions of dollars are invested in R&D to advance medical innovation. This institute will help Indiana attract additional global talent and will nurture partnerships across the state and across the country.”
 
“In the last decade, Indiana has come of age as a recognized leader in the life sciences, with demonstrated capabilities in biopharmaceuticals, medical devices, and diagnostics, as well as in the areas of animal health and crop sciences. The bio-landscape of Indiana is fertile ground for the Institute, and Lilly is proud to be a part of it. The IBRI is an R&D model that will help us address some of our most pressing medical needs,” added Dr. Lechleiter.